Louis Yu, Ph.D., has been appointed the newly created position of senior vice president of quality and compliance, AMRI. Dr. Yu will oversee quality and cGMP compliance in all divisions of AMRI, including Drug Discovery Services, API and Drug Product development and manufacturing. He reports to William S. Marth, AMRI’s president and CEO.
 
Dr. Yu has more than 30 years of leadership experience in thequality and R&D functions of branded and generic pharmaceutical companies. Most recently, he served as executive vice president, global quality and compliance for Perrigo, where he was responsible for strategic leadership and management of the global quality function. Prior to that, he served as vice president of quality for CV Therapeutics, now a division of Gilead. Earlier, he served as the most senior quality leader at Forest Laboratories, Solvay Pharmaceuticals and Par Pharmaceutical.
 
“AMRI has an outstanding reputation for quality service, and as we continue to expand our global network, it is critical that we continue to build on that reputation with our customers,” said Mr. Marth. “Louis’ deep quality experience at a number of pharmaceutical companies – both generic and branded – gives him the understanding of what our customers need. In addition, as AMRI grows toward our goal of achieving $1 billion in annual revenues by 2018, robust accountability for quality is an important business need. Louis is a welcome addition to our team.”